HepaMAb work programme

The project has been broken down into eight synergistic work packages that will:

  • Focus on lead optimization and generation of high producer cell lines and GLP production of lead monoclonal antibodies

  • Harness cutting edge in vitro and in vivo technologies to validate antibody efficacies at all stages of the development process

  • Perform industrial- and regulatory-standard tests for off-target activity of the lead antibodies

  • Establish and validate a therapeutic monoclonal antibody pipeline targeting alternative viral and host targets to be used as back-up and / or for future clinical development

  • Produce and purify lead MAbs and prepare production reports to support regulatory approval

  • Obtain regulatory approval then recruit to and carry out Phase I/IIa safety and efficacy clinical trials